Serious liver scarring from fatty liver disease is not only a problem of later life. A new UC San Diego-led study found that about one in four cases of cirrhosis caused by metabolic dysfunction-associated steatotic liver disease, or MASLD, occurred before age 50.
The research, published online Sept. 16 in Clinical Gastroenterology and Hepatology, found that people who develop cirrhosis before 50 have a distinct risk profile shaped by inherited genetic factors and type 2 diabetes.
The findings matter for adults in their 30s and 40s. Many people with fatty liver feel fine for years, and the study suggests that some tools doctors use to decide who needs further testing may overlook younger patients who already have advanced disease.
Screening Scores That Include Age Miss Younger Patients
Many commonly used liver fibrosis scores include age in their calculations. The Fibrosis-4 (FIB-4) index, for example, is a widely used first-line tool for estimating scarring risk, and its formula factors in age. Because younger people score lower on that factor, such tools may underestimate their risk.
In the study, nearly one-third of participants with early-onset cirrhosis had scores that would not typically trigger further evaluation under standard thresholds, according to the UC San Diego announcement.
"As current screening tools incorporate age, they miss almost a third of patients with early-onset MASLD cirrhosis," said Dr. Veeral Ajmera, a hepatologist at UC San Diego Health and first author of the study. "This study helps us identify which patients are at greatest risk and need a more accurate assessment of their liver disease."
Senior author Dr. Rohit Loomba, chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine, said younger adults who develop cirrhosis from MASLD "appear to have a unique combination of genetic susceptibility and metabolic risk factors that accelerate progression to advanced liver disease."
Inside the Biopsy-Confirmed Study Group
The team analyzed data from about 2,400 adults with MASLD confirmed by liver biopsy. Participants were enrolled in the national NASH Clinical Research Network, a multicenter research group supported by the National Institutes of Health. The researchers defined cirrhosis occurring before age 50 as early-onset MASLD cirrhosis and identified risk factors linked to it.
MASLD, formerly called nonalcoholic fatty liver disease, occurs when fat builds up in the liver in people with metabolic risk factors such as excess weight, high blood sugar, high cholesterol, or high blood pressure, as Northwestern Medicine's health library explains. Most people with fatty liver do not develop liver damage, but some progress to inflammation, scarring, and cirrhosis.
MedicalDaily Evidence Check: This is an observational analysis of about 2,400 biopsy-confirmed patients, published in a peer-reviewed journal. It identifies factors associated with early cirrhosis but does not prove that any single factor causes it. Because participants were enrolled at specialty research centers, the results may not reflect every community. The study was funded largely by the National Institute of Diabetes and Digestive and Kidney Diseases and other NIH sources. Loomba disclosed consulting relationships with numerous drugmakers, including Novo Nordisk, Eli Lilly, and Madrigal, and holds stock options in Sagimet Biosciences.
Adults Under 50 with Diabetes or Obesity Face Closer Questions
The study points to groups that may deserve earlier attention, including younger adults with type 2 diabetes, people with obesity, and those with elevated genetic risk. A family history of liver disease may be one clue to inherited risk.
"Cirrhosis is frequently silent until serious complications develop," Loomba said. "These results suggest that younger adults with type 2 diabetes, obesity or elevated genetic risk may benefit from more proactive liver assessment."
That silence is the core concern. Fatty liver disease often causes no symptoms early on, according to the Cleveland Clinic. When advanced disease does cause symptoms, they can include severe tiredness, weakness, loss of appetite, weight loss, fluid buildup, and bleeding.
Yellowing of the skin or eyes, vomiting blood, black stools, or sudden confusion can signal serious liver complications and require emergency care.
Cirrhosis is also a major risk factor for hepatocellular carcinoma, the most common type of liver cancer. Loomba said identifying high-risk patients earlier could create opportunities for appropriate cancer surveillance before liver cancer develops.
Testing, Costs, and Treatment Options
The study does not change formal screening guidelines. Still, adults under 50 with diabetes or obesity can reasonably ask their primary care clinician whether their liver has been checked and whether a noninvasive test, such as a liver stiffness scan, makes sense.
Routine blood tests can hint at liver trouble, but normal results do not rule out scarring. People who have had a reassuring fibrosis score may want to ask whether their age affected that result.
Access to specialized liver stiffness testing varies by insurance and location. Patients facing coverage denials can ask their provider about prior authorization or appeals.
Standard advice for managing MASLD includes reaching and keeping a healthy weight, eating a balanced diet, exercising regularly, and avoiding alcohol. Patients should tell their clinicians about all medicines and supplements they take, because some products can harm the liver.
Researchers expect MASLD-related liver disease to become more common as obesity and type 2 diabetes rates rise. The authors say their findings lay the groundwork for better risk prediction and screening, though improved tools still need to be developed and tested.
For now, younger age alone should not be taken as reassurance. Adults with diabetes, obesity, or a family history of liver disease may benefit from asking directly about their liver health rather than waiting for symptoms that may not appear until the damage is advanced.
Key Questions Answered
What did the UC San Diego-led study find? About 25% of MASLD cirrhosis cases in a group of roughly 2,400 biopsy-confirmed patients occurred before age 50, and inherited genetic risk and type 2 diabetes were key associated factors.
What is MASLD? It is the current name for fatty liver disease linked to metabolic risk factors. It was formerly called nonalcoholic fatty liver disease.
Why might younger patients be missed? Many fibrosis screening scores factor in age, which can make younger patients appear lower risk. Nearly a third of early-onset cases in the study had scores below standard thresholds.
Who should ask about liver testing? Adults under 50 with type 2 diabetes, obesity, or a family history of liver disease may want to discuss liver assessment with a clinician.
Does this change screening guidelines? No. The study informs future research, but official screening guidelines have not changed.
